Preliminary Study On Mechanism Of Anti-Osteoporosis Of Fructus Psoraleae And Fructus Psoraleae

Objective: This topic through the analysis of the recent advances in the treatment of osteoporosis,and screened scurfpea fruit and rhizoma drynariae as potential drug treatment,to better guide clinical application in osteoporosis therapy and drynaria fortunei malaytea scurfpea fruit,this study based on the method of network pharmacology analysis of rhizoma drynariae and scurfpea fruit core mechanism in the treatment of osteoporosis,By constructing osteoblast and osteoclast models in vitro,the new anti-osteoporosis targets of Psoralea and psoralea were revealed,which laid theoretical support for the enrichment of subsequent clinical treatment programs.Methods:1.Active components and effective targets of psoralea and psoralea were screened by TCMSP database;Disease-related genes were obtained from OMIM,TTD,Pharm Gkb,Drug Bank and Gene Cards databases.STRING database and Cytoscape3.7.2software are used for core network analysis.R software was used for GO analysis and KEGG enrichment analysis.2.In vitro models of osteoblasts and osteoclasts were constructed;TRACP activity of osteoclasts was detected by PNPP method.MTT assay was used for cell proliferation assay.ALP activity was determined by colorimetric method.The relative m RNA expressions of MAPK3,MAPK1,TP53 and RAGE were detected by q RT-PCR.Results:1.Network pharmacological study: 253 targets,1178 osteoporosis related genes,and 75 intersection targets of drug diseases were identified after weight removal of drug active ingredients in Gushibu and Psoru prescription.angelicin,backuchiol,Bavachalcone,isobavachin and eriodictyol,naringenin,kaempferol of psoralen.kaempferol,Eriodyctiol and β-sitosterol may be effective active ingredients in the treatment of osteoporosis.The core genes of the network were JUN,FOS,RSR1,MAPK3,MAPK1 and TP53.Network core signaling pathways lipid and atherosclerosis,chemical carcinogen-receptor activation,fluid shear stress and atherosclerosis,endocrine disorders,tumor necrosis factor signaling pathway,estrogen signaling pathway,and AGE/RAGE signaling pathway.2.In vitro experiments of osteoblasts and osteoclasts: Kaempferol and isopsoralen,the number of osteoclasts and TRAP enzyme activity in high-dose group were significantly lower than those in control group,low-dose group and medium-dose group(P <0.05),and the medium-dose group was significantly lower than the low-dose group and the medium-dose group(P <0.05),and the low-dose group was significantly lower than the control group(P <0.05).Kaempferol and isopsoralen,the relative proliferation rate and ALP activity of osteocytes in high-dose group were significantly higher than those in control group,low-dose group and medium-dose group(P <0.05),and the medium-dose group was significantly higher than the low-dose group and the medium-dose group(P<0.05),and the low-dose group was significantly higher than the control group(P <0.05).Kaempferol and isopsoralen,high dose osteocyte composition MAPK3 m RNA,MAPK1 m RNA,TP53 m RNA and RAGE m RNA were significantly lower than those in control group,low dose group and medium dose group(P <0.05),and medium dose group was significantly lower than low dose group and medium dose group(P <0.05).And the low dose group was significantly lower than the control group(P <0.05).Conclusion:1.In this study,network pharmacological analysis tools were used to explore the possible potential drug active ingredients of psoralea and psoralea in the treatment of osteoporosis,and based on important active ingredients,MAPK3,MAPK1,TP53 and AGE/RAGE signaling pathways were innovatively identified as drug targets.2.In this study,by further constructing the in vitro model of osteoblasts and osteoclasts,it was further elucidated that high concentration of kaempferol and isopsoralen could inhibit the expression of MAPK3,MAPK1,TP53 and AGE/RAGE signaling pathways,and thus play the purpose of inhibiting the proliferation of osteoclasts and promoting the proliferation of osteoblasts.